scholarly journals Percutaneous Ethanol Sclerotherapy of Symptomatic Nodules Is Effective and Safe in Pregnant Women: A Study of 13 Patients with an Average Follow-Up of 6.8 Years

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Tamas Solymosi ◽  
Zsolt Melczer ◽  
Istvan Szabolcs ◽  
Endre V. Nagy ◽  
Miklos Goth
Keyword(s):  
Percutaneous Ethanol Injection ◽  
Short Term ◽  
Ethanol Injection ◽  
Ethanol Sclerotherapy ◽  
Increased Risk ◽  
Long Term Follow Up ◽  
Nodule Volume ◽  
Ethanol Injection Therapy

Background.Because of the increased risk of surgery, thyroid nodules causing compression signs and/or hyperthyroidism are concerning during pregnancy.Patients and Methods.Six patients with nontoxic cystic, four with nontoxic solid, and three with overt hyperthyroidism caused by toxic nodules were treated with percutaneous ethanol injection therapy (PEI). An average of 0.68 mL ethanol per 1 mL nodule volume was administered. Mean number of PEI treatments for patients was 2.9. Success was defined as the shrinkage of the nodule by more than 50% of the pretreatment volume (V0) and the normalization of TSH and FT4 levels. The average V0 was 15.3 mL. Short-term success was measured prior to labor, whereas long-term success was determined during the final follow-up (an average of 6.8 years).Results.The pressure symptoms decreased in all but one patient after PEI and did not worsen until delivery. The PEI was successful in 11 (85%) and 7 (54%) patients at short-term and long-term follow-up, respectively. Three patients underwent repeat PEI which was successful in 2 patients.Conclusions.PEI is a safe tool and seems to have good short-term results in treating selected symptomatic pregnant patients. Long-term success may require repeat PEI.

Percutaneous Ethanol Injection of Hyperfunctioning Thyroid Nodules: Long-Term Follow-Up in 125 Patients

2008 ◽  
Vol 190 (3) ◽  
pp. 800-808 ◽  
Author(s):  
Luciano Tarantino ◽  
Giampiero Francica ◽  
Ignazio Sordelli ◽  
Pasquale Sperlongano ◽  
Domenico Parmeggiani ◽  
...  
Keyword(s):  
Thyroid Nodules ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
Long Term Follow Up

Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma

2001 ◽  
Vol 12 (1) ◽  
pp. 74-76 ◽  
Author(s):  
L. Arrivé ◽  
A. Vurgait ◽  
L. Monnier-Cholley ◽  
M. Lewin ◽  
P. Balladur ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Percutaneous Ethanol Injection ◽  
Ethanol Injection ◽  
Long Term Follow Up

Macitentan in the treatment of pulmonary arterial hypertension

2021 ◽  
Vol 17 (1) ◽  
pp. 49-58
Author(s):  
Rodrigo Zebadúa ◽  
Andrea Priscila Hernández-Pérez ◽  
Antonio García ◽  
Nayeli Zayas ◽  
Julio Sandoval ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Progressive Disease ◽  
Functional Class ◽  
Short Term ◽  
Increased Risk ◽  
Long Term Follow Up ◽  
Pulmonary Arterial

Pulmonary arterial hypertension (PAH) is an uncommon but lethal and progressive disease in which prostacyclin, nitric oxide and endothelin-1 pathways are disturbed and contribute to the pathophysiology of this disease. Endothelin receptor antagonists are a class of drugs that have been approved as PAH therapy. Macitentan is a lipophilic, tissue specific, dual receptor antagonist with a higher potency than bosentan and a reduced risk of hepatic injury. Macitentan has shown a reduction in morbidity and mortality due to PAH at long-term follow-up and improvements in hemodynamics, exercise capacity and functional class at the short term. Its main adverse events are nasopharyngitis, bronchitis and an increased risk of anemia. We review the clinical data of macitentan and its use in PAH.

scholarly journals Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

2019 ◽  
Vol 26 (8) ◽  
pp. 924-935
Author(s):  
Kevin Ahrweiller ◽  
Chloé Rousseau ◽  
Emmanuelle Le Page ◽  
Emma Bajeux ◽  
Emmanuelle Leray ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Multiple Sclerosis ◽  
Secondary Progressive Multiple Sclerosis ◽  
Short Term ◽  
Secondary Progressive ◽  
Increased Risk ◽  
Disability Status ◽  
Long Term Follow Up

Background: Changes in relapse activity during secondary progressive multiple sclerosis (SPMS) need to be accurately characterized in order to identify patients who might benefit from continuing disease-modifying therapies. Objective: To describe relapse occurrence in patients with SPMS during long-term follow-up and assess its impact on disability worsening. Methods: This retrospective cohort study included 506 patients. We assessed the influence of relapses on time from SPMS onset to an Expanded Disability Status Scale score of 6 (EDSS 6), and on irreversible worsening of EDSS scores across different periods. Results: The annualized relapse rate (ARR) decreased with patient’s age (mean reduction of 43% per decade) and SPMS duration (mean reduction of 46% every 5 years). Post-progression relapses were associated with shorter time from secondary progressive (SP) phase onset to EDSS 6 (hazard ratio (HR) = 1.29, 95% confidence interval (CI) = (1.01, 1.64)). Relapse occurrence during the first 3 years and 3–5 years after SP onset was associated with an increased risk of irreversible EDSS worsening (OR = 3.12 (1.54, 6.31) and 2.04 (1.16, 3.58)). This association was no longer significant after 5 years. Conclusion: The occurrence of relapses was a marker of short-term disability progression during early SPMS, but did not have decisive impact in later SPMS.

Sign in / Sign up

Export Citation Format

Share Document